YolTech Therapeutics is set to commence a trial of its in vivo gene editing therapy, YOLT-204, aimed at treating TDT.

The study found that the number of advanced therapy Phase I trials in the UK nearly doubled since the same time in 2023.

To observe the effects of coffee consumption on HNC risk, a study published in Cancer utilised pooled data from the INHANCE ...

Results from the single-arm trial saw 63.5% of patients able to avoid the symptoms of Atrial fibrillation over the course of ...

The FDA has granted approval for Zydus to proceed with the Phase II(b) trial of Usnoflast for amyotrophic lateral sclerosis (ALS) treatment.